Selpercatinib
ATC L01EX22 · 9 markets · 41 records
AU 12 records · 7 strengths
- 80 mgcapsuleRETEVMORETEVMO selpercatinib 80 mg immediate release capsules
- 40 mgcapsuleRETEVMORETEVMO selpercatinib 80 mg immediate release capsules
- 80 mgtabletRETEVMORETEVMO selpercatinib 40 mg film-coated tablets blister pack
- 40 mgtabletRETEVMORETEVMO selpercatinib 40 mg film-coated tablets blister pack
- 160 mgtabletRETEVMO selpercatinib 40 mg film-coated tablets blister pack
- 120 mgtabletRETEVMO selpercatinib 40 mg film-coated tablets blister pack
Records without a stated strength · 1 RETEVMO
US 6 records · 6 strengths
GB 4 records · 4 strengths
- 80 mgcapsuleRetsevmo 40mg capsules
- 40 mgcapsuleRetsevmo 40mg capsules
- 80 mgtabletRetsevmo 40mg capsules
- 40 mgtabletRetsevmo 40mg capsules
CA 4 records · 4 strengths
SG 4 records · 4 strengths
- 80 mgcapsuleTANSTRIVE HARD CAPSULES 80MG
- 40 mgcapsuleTANSTRIVE HARD CAPSULES 80MG
- 80 mgtabletTANSTRIVE TABLETS 80MG
- 40 mgtabletTANSTRIVE TABLETS 80MG
ES 4 records · 4 strengths
- 80 mgcapsuleRetsevmo 40mg capsules
- 40 mgcapsuleRetsevmo 40mg capsules
- 80 mgtabletRetsevmo 40mg capsules
- 40 mgtabletRetsevmo 40mg capsules
TW 2 records · 2 strengths
- 80 mgcapsuleRETSEVMO hard capsules 40mg銳癌寧膠囊80毫克
- 40 mgcapsuleRETSEVMO hard capsules 40mg銳癌寧膠囊40毫克
HK 2 records · 1 strengths
Records without a stated strength · 1 Retsevmo 40mg capsules
EU 1 records · 1 strengths
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Records without a stated strength · 1 Retsevmo 40mg capsules
| Strength / form / release | US | GB | CA | AU | SG | ES | TW | HK | EU |
|---|---|---|---|---|---|---|---|---|---|
| 80 mg capsule | RETEVMO | Retsevmo 40mg capsules | RETEVMO | RETEVMO RETEVMO selpercatinib 80 mg immediate release capsules | TANSTRIVE HARD CAPSULES 80MG | Retsevmo 40mg capsules | RETSEVMO hard capsules 40mg 銳癌寧膠囊80毫克 | ||
| 40 mg capsule | RETEVMO | Retsevmo 40mg capsules | RETEVMO | RETEVMO RETEVMO selpercatinib 80 mg immediate release capsules | TANSTRIVE HARD CAPSULES 80MG | Retsevmo 40mg capsules | RETSEVMO hard capsules 40mg 銳癌寧膠囊40毫克 | ||
| 80 mg tablet | RETEVMO | Retsevmo 40mg capsules | RETEVMO | RETEVMO RETEVMO selpercatinib 40 mg film-coated tablets blister pack | TANSTRIVE TABLETS 80MG | Retsevmo 40mg capsules | |||
| 40 mg tablet | RETEVMO | Retsevmo 40mg capsules | RETEVMO | RETEVMO RETEVMO selpercatinib 40 mg film-coated tablets blister pack | TANSTRIVE TABLETS 80MG | Retsevmo 40mg capsules | |||
| 160 mg tablet | RETEVMO | RETEVMO selpercatinib 40 mg film-coated tablets blister pack | |||||||
| 120 mg tablet | RETEVMO | RETEVMO selpercatinib 40 mg film-coated tablets blister pack | |||||||
unknown | RETEVMO | Retsevmo 40mg capsules | Retsevmo 40mg capsules |
Scroll horizontally for more markets →
Each country column shows the locally registered trade names — not translations.
“not disclosed” means the source does not publish the strength — it does not mean the product has none.
Hong Kong records are name/ingredient-level only: no strength, dosage form or registration status; on the register does not prove current supply.
Australia ARTG data has no registration-status column, so status is shown as unknown; being on the register does not mean currently marketed.
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.